TriSalus Life Sciences (TLSI) Short term Debt (2022 - 2023)

TriSalus Life Sciences (TLSI) reported Short term Debt of $10.0 million for Q2 2023, up 115.88% quarter-over-quarter from $4.7 million in Q1 2023.

TriSalus Life Sciences (TLSI) Short term Debt (2022 - 2023) Analysis & Trends

TriSalus Life Sciences has reported Short term Debt for 2 years, with the latest figure at $10.0 million in Q2 2023.

For the quarter ending Q2 2023, Short term Debt changed N/A year-over-year to $10.0 million; the trailing twelve-month figure through Jun 2023 stood at $10.0 million (changed N/A YoY), and the FY2022 full-year result was $2.5 million, changed N/A from the prior year.
Short term Debt for Q2 2023 stood at $10.0 million, up from $4.7 million in the prior quarter.
The five-year high for Short term Debt was $10.0 million in Q2 2023, with the low at $2.5 million in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	154.42 Bn	147.76 Bn	6.27 Bn
2	Stryker	118.12 Bn	115.25 Bn	3.81 Bn
3	Medtronic	101.72 Bn	93.55 Bn	5.76 Bn
4	Boston Scientific	67.19 Bn	65.98 Bn	3.61 Bn
5	Edwards Lifesciences	50.69 Bn	47.02 Bn	1.29 Bn
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn
7	Dexcom	28.09 Bn	26.97 Bn	750.30 Mn
8	GE HealthCare Technologies	28.08 Bn	26.02 Bn	1.98 Bn
9	Steris	19.80 Bn	19.37 Bn	697.10 Mn
10	TriSalus Life Sciences	209.25 Mn	152.70 Mn	7.67 Mn

Download Data